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Lung cancer is the most contributor of cancer cause death in the world. Lung cancer is related to cigarette consumption 
and genetic factor. Nicotine derived nitrosamine ketone is the most important inducer of lung cancer associated with DNA 
Mutations resulting in the activation of Kirsten rat sarcoma viral (KRAS) oncogenes. DNA Mutation in Lung cancer is mostly 
presence by epidermal growth factor receptor (EGFR) mutations. There were seven potential biomarkers to detect early 
lung cancer, whereas carcinoembryonic antigen (CEA), neuron specific enolase (NSE), cytokeratin-19 fragments (CYFRA 
21-1), alpha-fetoprotein (AFP), cancer antigen 125 (CA-125), CA-199 and ferritin. The use of biomarkers in combination 
can improve the accuracy in diagnosing lung cancer. Other biomarkers include KRAS mutations, B-type Raf kinase (BRAF) 
mutation, mesenchymal-epithelial transition factor (MET) amplification and Excision repair cross-complementing group 1 
(ERCC1) can be used to see whether there are any genetic mutations that lead to lung cancer. Treatment of lung cancer with 
chemotherapy can be done using tyrosine kinase inhibitors and monoclonal antibodies.
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Introduction
The signaling pathway of epidermal growth factor (EGF) 
receptor (EGFR), is activated in more than half of the 
patients with non-small cell lung cancer (NSCLC). This 
activation can be a result of overexpression of the protein, 
the increasing number of genes copies or genetic mutation. 
Estrogen receptor binding (ErbB) receptor family consists 
of four receptor tyrosine kinases: EGFR, also called ErbB1 
or human epidermal receptor (HER)1; ErbB2 (HER2/neu), 
ErbB3 (HER3), and ErbB4 (HER4).1,2 Insufficient ErbB 
signaling in humans is associated with the development of 
neurodegenerative diseases, such as multiple sclerosis and 
Alzheimer's disease.
 Binding of receptor and ligand induces receptor 
dimerization, resulting in the phosphorylation of tyrosine 
residues in the kinase domain.3,4 These phosphotyrosines 
recruit partner proteins that trigger intracellular signaling 
cascades, chiefly through the mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) 
pathway.5 This pathway is involved in the induction of cell 
proliferation, protection from apoptosis,6,7 activation of 
angiogenesis and development of metastasis. Erlotinib and 
gefitinib were developed as reversible and highly specific 
small-molecule tyrosine kinase inhibitors that competitively 
block the binding of adenosine triphosphate to its binding 
site in the tyrosine kinase domain of EGFR.8 Erlotinib and 
C e l l  a n d 
B i o p h a r m a c e u t i c a l 
I n s t i t u t e
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gefitinib seem to be very effective in treating tumors with 
gene mutations that activate EGFR. The tumor may depend 
on the activity of the EGFR pathway for their survival.9
 EGFR is single chain transmembrane glycoproteins 
consisting of an extracellular ligand-binding ectodomain, a 
transmembrane domain, a short juxtamembrane section, a 
tyrosine kinase domain and a tyrosine-containing C-terminal 
tail. The EGFR tyrosine kinase regulates cell proliferation 
and survival through the automatic activation of EGFR 
itself or two pathways mediating inter downstream: the 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha (PIK3CA) / Akt1 / mammalian target of 
rapamycin (mTOR) pathway and the  Ras / Raf / MAPK 
pathway. The ligand-binding induced dimerization of 
tyrosine residues in the cytoplasmic domains.10 This 
activation of EGFR initiates signaling cascades which 
induce critical cellular responses, such as proliferation, 
differentiation, motility and survival.
EGFR alterations in lung cancer
A comprehensive literature review indicated that 569 
mutations were found in 2,880 lung cancer patients. 
Mutation distribution of EGFR is as follows: 48% in exon 
19; 43% in exon 21; 4% in exon 20 and 3% in exon 18. 
EGFR mutations, except EGFRvIII, are rarely found in 
the squamous cell and large cell carcinomas. Thus tyrosine 
kinase inhibitor (TKI) therapy may not be a relevant therapy 
for patients with those tumors. In contrast, EGFR mutations 
were found in 10% of 375 adenocarcinomas and 26% of 
the 86 cases designated as bronchioloalveolar carcinomas.11 
 Mutations with constitutive activation of the receptor 
tyrosine kinase are often associated with either sensitivity 
or resistance to EGFR TKI.12 The response-associated 
mutations are linked with response rates of 47% in patients 
treated with either erlotinib or gefitinib.13 EGFR mutations 
of exons 18-24 in tumors from 10 gefitinib-responsive and 
7 erlotinib-responsive demonstrated that EGFR mutations 
were present in 7 of 10 (70%) gefitinib-responsive and in 5 
of 7 (71%) erlotinib-responsive tumors.14
Treatment
Guidelines for the diagnostic with known or suspected 
lung cancer include obtaining a thorough history, physical 
examination and appropriate elaboration tests to screen for 
metastatic disease. Type of lung cancer confirmation by 
cytology is important before treatment can be determined.15 
NSCLC
Surgery is the treatment of choice for individuals with 
early-stage NSCLC. The type of surgical procedure 
depends on tumor location, the patient’s comorbidities 
and the potential effects on long-term pulmonary function. 
Patients with positive surgical margins were evaluated for 
additional treatment, which typically includes a radiation/
chemotherapy. Radiation therapy is the main treatment for 
people who have comorbidities, such as heart disease or 
severe lung disease, or who are poor surgical candidates.16 
Patients with complete resection and those with residual 
nodal disease found at surgery, may be considered for 
postoperative radiation therapy. Healthy IIIB patients 
with clinical T4N0 of satellite tumor in the same lobe or 
involvement carinal should be referred to a thoracic surgeon 
for possible resection. People with stage IV NSCLC have a 
poor prognosis with a median survival of 8-10 months and 
1-year survival rate of 30-35%.15,16
Small cell lung cancer (SCLC) 
SCLC usually is more aggressive than NSCLC. Distant 
metastasis is common at initial presentation. Primary 
treatment usually consists of combination chemotherapy, 
which may be combined with radiation therapy. Limited-
stage disease can potentially be cured with combination 
chemotherapy and radiation therapy. Surgical resection 
may be considered in rare situations when a patient 
has limited SCLC. Around 50-60% of the patients who 
achieved a complete response after chemotherapy induction 
will develop brain metastases within 2 years. The brain 
is the only site of metastasis in 20-30% of these patients. 
Consequently, people who achieve complete remission are 
offered prophylactic cranial irradiation to decrease the risk 
of central nervous system involvement. If patients relapse 
after an initial response to treatment or if they do not respond 
to initial treatment, further chemotherapy is usually offered, 
depending on the patient’s previous response to first-line 
therapy. In patients with extensive disease, radiation therapy 
may be used for palliation.15,16
Chemotherapy
NSCLC management diagnosed until the disease has spread 
beyond the primary site; approximately 55% of patients have 
the metastatic (stage IV) disease at diagnosis.17 For these 
patients, chemotherapy is the foundation of their treatment 
and critical in determining their survival and quality of life. 
Platinum-based therapy is the mainstay of chemotherapy for 
NSCLC and is usually given in combination with a tubulin 
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binding agent (TBA); including the taxanes (paclitaxel, 
docetaxel), vinca alkaloids (vinorelbine, vincristine), a 
camptothecin analog (irinotecan, topotecan), gemcitabine, 
or pemetrexed. Despite an expanding panel of chemotherapy 
agents and emerging data regarding the most effective ways 
to deploy such agents, tumor cell resistance to chemotherapy 
agents continues to pose a significant challenge in the 
management of human neoplasms. 
 Chemoresistance may be innate or acquired and 
may apply to a single agent or a class of agents with 
the same/similar antineoplastic mechanisms of action. 
Chemoresistance is a multifaceted problem with diverse 
clinical manifestations that requires an understanding of 
both basic mechanisms and evolution of such resistance as 
cancer progress. Active efflux of chemotherapeutic agents 
is achieved via ATP-binding cassette (ABC) transporters 
(including P-glycoprotein [P-gp] and multi-drug resistance 
proteins [MDRs]). This mechanism contributes to resistance 
to anthracyclines, taxanes, platinum agents, vinca alkaloids 
and topoisomerase inhibitors. Modification of the drug 
target, including mutation of the binding site or in the case of 
TBAs, has a change in the relative proportion of the various 
tubulin isoforms, mediate resistance to taxanes, antifolates 
and topoisomerase inhibitors. Changes or mutations in the 
mitotic checkpoint signaling, allowing tumor cells to bypass 
or overcome that exert antimitotic agent/proapoptotic 
effects, mediating resistance to platinum agents, taxanes 
and anthracyclines.
 Chemoresistance is common in NSCLC. In a study, 
extreme or intermediate resistance to carboplatin was 
documented in 68% (1056/1565) of samples and cisplatin 
resistance was in 63% (1409/2227) of samples.18 Resistance 
to doxorubicin, etoposide, gemcitabine, vinorelbine, 
paclitaxel, docetaxel and topotecan was reported in 75, 
63, 72, 42, 40, 52 and 31% of samples, respectively.18 
All NSCLC patients will eventually develop resistance to 
the chemotherapeutic agents to which they are exposed, 
even with a good initial response, and most will receive 
two or three lines of therapy. The challenge in managing 
patients with NSCLC is the need to establish a long-term 
view, taking into account the likelihood of developing 
chemoresistance and the effect of using an agent at each line 
of therapy. Currently, there is no reliable strategy available 
to guide treatment selection from first-line through all 
subsequent lines of therapy to avoid the development of 
chemoresistance, although active clinical investigations are 
ongoing.18 
 Some platinum analogs are in early clinical 
development including picoplatin (cisplatin analog). This 
agent has demonstrated clinical activity among patients 
with platinum-refractory SCLC in Phase II and III trials as a 
second-line treatment following platinum therapy.19 
 ABT-751 (a sulfonamide) is a novel investigational 
TBA that binds to the colchicines site of tubulin and 
inhibits the polymerization of microtubules. Early clinical 
data for this agent is encouraging in heavily pretreated 
patients, including those previously treated with platinum-
based regimens.20 The epothilones, including ixabepilone, 
sagopilone and patupilone, are a novel class of TBAs. The 
epothilones bind tubulin in the same location as the taxanes. 
However, the molecular nature of epothilone binding is 
fundamentally different, involving a group of alternative 
amino acids.21 Importantly, the epothilones retain activity 
in cell lines resistant to taxanes. The epothilones appear 
to decrease III-tubulin expression and restore sensitivity 
of tumor cells to other chemotherapeutic agents including 
cisplatin and taxanes. In breast cancer cells, ixabepilone 
appears to be less sensitive to mutational changes within the 
III-tubulin gene that impair taxane binding,22 and better at 
suppressing the overall dynamicity of III-tubulin compared 
with paclitaxel non-taxane resistant breast cancer cells. 
Also, in vitro data suggests that ixabepilone may overcome 
taxane resistance in breast cancer cell lines through 
preferential binding to the III-tubulin isoform.23 A Phase 
II study with patupilone resulted in a response rate of 11% 
among 47 patients with NSCLC. The epothilones can offer 
an alternative for patients with congenital taxane resistance 
include those with pre-treatment of high-level III-tubulin.
Erlotinib and gefitinib
EGFR alterations have prompted the development of two 
classes of anti-EGFR agents: monoclonal anti-EGFR 
antibodies (such as cetuximab, panitumumab, etc.) and 
small molecule TKIs directed against EGFR tyrosine kinase 
(such as gefitinib, erlotinib, etc.). The results of the clinical 
trials indicated that many of the tumors harboring mutant 
EGFR are highly sensitive to EGFR TKIs, with up to 70% 
demonstrating a significant clinical response.24 Recent 
studies have provided more compelling evidence of the 
clinical benefits of anti-EGFR treatment in the appropriate 
setting.25 Evidence from the large phase III randomized 
Iressa Pan-Asia Study trial has prompted the American 
Society of Clinical Oncology to issue a provisional clinical 
opinion, recommending the testing of EGFR mutational 
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status in patients being considered for first-line EGFR TKI 
therapy owing to their demonstrated benefit on progression-
free survival.26 
 Erlotinib and gefitinib have been studied in a variety 
of settings in clinical trials. In two parallel phase III 
studies, erlotinib and gefitinib were compared with placebo 
in patients with advanced NSCLC in whom standard 
chemotherapy had failed. In a National Cancer Institute 
of Canada Clinical Trials Group (NCIC CTG) BR.21 trial 
(NCT00036647), 731 patients with stage IIIB or IV NSCLC 
were randomly assigned to receive either erlotinib (at a 
daily dose of 150 mg) or placebo. Erlotinib was superior 
compared to placebo in the analysis of overall survival (6.7 
vs. 4.7 months, p=0.001) and progression-free survival (2.2 
vs. 1.8 months, p<0.001).27 Meanwhile, in Iressa Survival 
Evaluation in Lung Cancer (ISEL) trial (NCT00242801), 
the effects of gefitinib (250 mg daily) were compared with 
placebo. Gefitinib was superior to placebo in terms of time to 
treatment failure (3.0 vs. 2.6 months, p<0.001). However, no 
significant differences were observed in overall survival.27
 Erlotinib (similar to that of gefitinib) intracellularly 
binding to the ATP-binding site of the tyrosine kinase 
domain of EGFR, which blocks the catalytic activity of 
the kinase, thereby inhibiting downstream signaling of 
the pathways responsible for cellular proliferation. The 
T790M mutation, one mechanism of resistance to EGFR 
tyrosine kinase inhibition, is detected in approximately 50% 
of patients who have a relapse while receiving an EGFR 
tyrosine kinase inhibitor. T790M causes steric hindrance of 
the binding of the tyrosine kinase inhibitor and promotes 
constitutive activation of the EGFR mutated kinase. Thus, 
downstream signaling occurs despite the use of a tyrosine 
kinase inhibitor.27
Monoclonal antibody therapy
Another target for lung cancer is the programmed death 1 
(PD-1). PD-1 receptor, which is expressed on activated T 
cells, is engaged by PD-ligand 1 (PD-L1) and PD-L2, which 
is expressed by tumor cells and infiltrating immune cells. 
Tumor PD-L1 expression is prevalent in NSCLC, and the 
interaction of PD-L1/-L2 and PD inhibit activation of T-cells 
and promotes tumor immune escape (i.e., the mechanism by 
which tumor cells escape recognition and elimination by the 
immune system).28
 Monoclonal antibodies, such as cetuximab and 
panitumumab, are either chimeric mouse-human fully 
humanized antibodies targeting the EGFR extracellular 
domain, leading to blockade of ligand-activated signal 
transduction and receptor dimerization. Panitumumab has a 
high affinity for EGFR.29 The binding of the antibody starts 
EGFR internalization and degradation, in which leads to 
signal termination. The treatment has shown benefit to the 
clinical outcome when added to chemotherapy. However, 
this class of treatment only inhibits ligand-dependent 
activation of EGFR and not auto-phosphorylation of the 
tyrosine kinase domain via constitutive activation. These 
mutations may still activate the downstream pathways, 
and up-regulate cell cycle progression, cell growth and 
angiogenesis.28
Nivolumab
Nivolumab is a human Immunoglobulin G4 (IgG4) PD-1 
immune-checkpoint inhibitor, an antibody that disrupts 
PD-1-mediated signaling and restores antitumor immunity. 
Nivolumab is PD-1 checkpoint inhibitor that demonstrated 
a survival benefit with improved safety profiles. Benefits 
were observed, regardless of the level of expression of 
PD-L1. Further research is needed to identify relevant 
biomarkers that have sufficient sensitivity and specificity to 
predict which patients are most likely to benefit.29
Pembrolizumab
Pembrolizumab is a human monoclonal antibody against 
the PD-1, which has antitumor activity in advanced 
NSCLC with increased activity in tumors that express 
PD-L1. Pembrolizumab was associated with significantly 
longer overall survival than chemotherapy, despite the low 
number of deaths observed and the potentially confounding 
effect of crossover from the chemotherapy group to the 
pembrolizumab group.30 By data from the second interim 
analysis, the data and safety monitoring committee 
recommended to stop the trial and offer the remaining 
patients in the chemotherapy group to take pembrolizumab. 
At the time of data cutoff, 35.4% of the enrolled patients 
had died and 43.7% of the patients in the chemotherapy 
group had crossed over to receive pembrolizumab. These 
data underscore the substantial benefit of pembrolizumab as 
initial therapy for advanced NSCLC with PD-L1 expression 
on at least 50% of tumor cells. The safety profile of 
pembrolizumab observed in this trial was consistent with 
that seen previously with pembrolizumab for the treatment 
of advanced NSCLC31,32 and other tumor types.
 Immune-mediated adverse events (including 
pneumonitis) occurred more frequently in the pembrolizumab 
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group than in the chemotherapy group, whereas cytopenia 
is more frequently in the chemotherapy group than in the 
pembrolizumab group; these results are consistent with 
the mechanism of action for each therapy. Most immune-
mediated events were grade 1 or 2 severity, and none led 
to death. However, the overall safety profile appeared to be 
better with pembrolizumab than with chemotherapy.33
New biomarker for lung cancer diagnosis 
The tendency for tumor biomarkers to be detected in the 
serum in the early stages of the disease has become an 
area of interest for clinicians. This study aimed to evaluate 
the efficiency of 7 tumor biomarkers, i.e., carcinogens 
embryonic antigen (CEA), neuron-specific enolase (NSE), 
cancer antigen-125 (CA-125), cytokeratin-19 fragments 
(CYFRA-21-1), CA-19.9, ferritin and alpha-fetoprotein 
(AFP), either independently or in combination for the 
diagnosis of lung cancer. The observed level of CEA, 
NSE, CA-125, CYFRA-21-1 and CA-19.9 in patients with 
pathologically-confirmed lung cancer was significantly 
higher than in patients with benign lung diseases or 
control subjects. CEA+NSE+CA-125 showed the highest 
sensitivity for small-cell carcinoma at 83.33%, while 
the CEA+NSE+CA-125+CYFRA-21-1 showed 94.11% 
sensitivity for squamous cell carcinoma. The combination 
of six biomarkers i.e., CEA+NSE+CA-125+CYFRA-21-
1+CA-19.9+ferritin, indicate the sensitivity of 80.49% for 
adenocarcinoma. Combining biomarkers significantly help 
in the diagnosis of lung cancer. However, this increased 
sensitivity to the combination was accompanied by 
decreased specificity for lung cancer subtypes. Combining 
the right biomarker improves sensitivity and help with the 
diagnosis of lung cancer.34
 Cumulatively, these findings suggest that a single 
biomarker may not provide sufficient clues for the 
detection of lung cancer. As cancer are heterogeneous and 
have distinctive genetic and epigenetic profiles, a single 
biomarker also cannot provide sufficient information 
for predicting treatment response and patient outcome.35 
However, considering the complexity of tumor origin and the 
heterogeneity of tumor antigen expression, a combination 
of biomarkers represents a useful means of assessing the 
histologic subtypes of lung cancer. The optimal specificity 
for each lung cancer subtype may be achieved by the 
appropriate combination of biomarkers.34
 Reported clinical trials have produced favorable 
responses using PD-1/PD-L1 blockade as monotherapy 
and combined with the CTLA-4 blockade.36 Identifying 
ideal biomarker is needed in optimizing and personalizing 
immunotherapy because the clinical benefit is not observed 
in all patients, since every patients has their own unique 
variations of the human genome, due to the combination of 
genetic variations and environment influence.37 The utility 
of PD-L1 expression as a biomarker has varied based on 
different clinical trials and immunohistochemistry (IHC) 
assays. Also, response to immune checkpoint inhibition is 
complicated by PD-L1 expression as a marker influenced 
by a dynamic tumor microenvironment. Currently, there is 
no consensus on whether the PD-L1 expression is an ideal 
marker for patient selection. Further studies are needed to 
assess the value of predictive biomarkers for patient selection 
and treatment response which has a promise for alternative 
markers, including T-cell IHC, other immunologic markers, 
T-cell receptor clonality and somatic mutational burden.
Wild-type EGFR
Wild-type EGFR seems to be an important marker for 
EGFR TKI resistance primer. Clinical trials of Iressa Pan-
Asia Studies show that most tumors without EGFR tyrosine 
kinase domain mutations detected are not sensitive to 
gefitinib.38 Tumors with wild-type EGFR frequently harbor 
somatic mutations in other genes that affect key pathways in 
lung adenocarcinoma. Thus, the primary drug insensitivity 
may be linked to the absence of drug-sensitizing mutations 
in EGFR and are more likely to be the result of a mutation 
in another gene.39
Kirsten rat sarcoma viral (KRAS) mutations 
KRAS has a role in the process of EGFR signaling. 
Activating mutations of KRAS is present in 25-35% of TKI 
non-responsive cases.40 EGFR and KRAS mutations are 
rarely detected in the same tumor, suggesting that they may 
perform similar functional roles in lung tumorigenesis.41 
KRAS mutation is a negative predictor of response to 
monoclonal antibodies anti-EGFR and is also an important 
mechanism of resistance to TKI in lung adenocarcinoma. 
A meta-analysis provides empirical evidence that somatic 
mutations of the KRAS oncogene are a negative predictor 
of a very specific response to single agent EGFR TKIs in 
advanced lung cancer, mostly adenocarcinomas.42 In 1470 
of lung cancer of 22 publications, of which 231 cases have 
KRAS mutations (16%).43 The mutations were more common 
in adenocarcinomas compared than other histological types 
of lung cancer (26 vs. 16%). The objective response rate 
of patients with KRAS mutant is 3% (6/210), whereas the 
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objective response rate of patients with wild-type KRAS is 
26%. Like most KRAS mutations were detected in codons 
12 and 13 of exon 2, an alternative algorithm-screening 
is performed for KRAS mutation analysis, followed by 
EGFR mutation assay. Mutations in KRAS are primary 
resistance to gefitinib and erlotinib.40 KRAS mutations 
are almost exclusively detected in codons 12 and 13 of 
exon 2, resulting in EGFR independent intracellular signal 
transduction activation.44
B-type Raf kinase (BRAF) mutations
The B-Raf gene encodes a protein that has a key role 
downstream of KRAS in the cell signaling pathway activating 
important cell functions, including cell proliferation and 
survival.45 Both K-Ras and B-Raf genes are part of the 
signaling cascade for the EGFR family proteins. The BRAF 
protein is a serine/threonine protein kinase that is activated 
by KRAS in a GTP-dependent manner.46 Proteins of BRAF 
mutant increased kinase activity and can transform NIH3T3 
cells. KRAS function is not required for the growth of 
cancer cells with the BRAF mutation.47 Among the 697 
patients with lung adenocarcinoma, BRAF mutation found 
in 18 patients (3%). The frequency of mutations in BRAF 
V600E (>50%), G469A (39%) and D594G (11%) found in 
exon 15, 11 and 15, respectively. All patients with BRAF 
mutations are smokers or former smokers. BRAF main 
function is believed to be mediated by phosphorylation 
and thus activate MAPK1, MAP2K1 and MAP2K2 path.46 
Mutations in BRAF have been shown to interfere the 
response to panitumumab or cetuximab in patients with 
colorectal carcinoma. BRAF mutations are found in 1-3% 
of lung cancer, mostly adenocarcinomas.47 BRAF exon 15 
mutations were tested on 96 paired samples of primary 
lung adenocarcinomas and corresponding locoregional 
lymph node metastases.48 BRAF mutations were observed 
in two patients with KRAS mutations, demonstrating the 
possibility of both mutations in BRAF and KRAS occurring 
in the same tumor.
 The initial retrospective work on mutant BRAF’s 
effect on EGFR-targeted therapy was performed on a 
cohort of 132 metastatic colorectal cancer patients. The 
results showed that none of the patients who experienced 
a response displayed BRAF mutations, whereas 11 of 79 
(14%) non-responders carried a BRAF V600E allele. As 
BRAF mutations are mutually exclusive to EGFR and 
KRAS mutations, it is likely to be associated with lack of 
response to EGFR TKIs.49
Mesenchymal-epithelial transition factor (MET) 
amplification
MET is a single pass tyrosine kinase receptor essential for 
embryonic development, organogenesis and wound healing. 
MET also contributes to primary and acquired resistance to 
EGFR TKI. MET is located on chromosome 7q21, which 
encodes a tyrosine kinase and hepatocyte growth factor 
receptor (HGFR).50 MET amplification is associated with 
acquired resistance to EGFR TKI through a mechanism 
called the kinase switch.51 Overall, MET amplification has 
been reported in approximately 20% of tumors from patients 
with resistance which is obtained. MET amplification occurs 
in both squamous cell carcinoma and adenocarcinoma.52 In 
an in vitro study, MET amplification was associated with 
an increased concentration of phosphorylated HGFR. MET 
amplification correlates with poor prognosis in lung cancer 
study of surgical resection, including 241 adenocarcinomas, 
139 squamous cell carcinoma and 67 other types of tumors. 
Aberrant MET signaling may have a key role in the 
development of acquired resistance to treatment with EGFR 
TKI.28 Clinical relevance of MET amplification has been 
investigated by examining tumor biopsies from patients 
who developed acquired resistance to gefitinib or erlotinib. 
MET status was assessed in a sample copy of re-biopsy 
from 18 patients with lung cancer during the development of 
secondary resistance following an initial partial response.53 
In another study, MET amplification was identified in 9 of 
43 (21%) patients who have developed resistance secondary 
to EGFR TKIs in contrast to 2 of 62 (3%) patients with 
EGFR mutation known sensitivities also have amplification 
of MET. Identification MET amplification has led to the 
development of HGFR-targeted TKI.54
Excision repair cross-complementing group 1 (ERCC1) 
expression
The significant prognostic of ERCC1 was accessed with 
real-time quantitative-PCR in surgical specimens from 
chemotherapy-naive patients. Investigational results of 1,207 
lung cancer patients with the relationship between EGFR 
mutation status and ERCC1 gene expression indicated that 
EGFR mutated cancers are more likely to be categorized 
as ERCC1 low and, therefore, platinum sensitive.55 IHC 
evaluation of the ERCC1 expression in tumors from 
130 patients revealed that ERCC1 was expressed in 10% 
of EGFR-mutated tumors and in 70% of EGFR wild-
type tumors. Patients with low ERCC1 expression had a 
longer overall survival compared with the patients with 
 47
Lung Cancer Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal AntibodiesSemadhi MP, et al.
high ERCC1 expression. Although most studies indicate 
a consistent association between ERCC1 expression level 
and responsiveness to cisplatin-based therapy, another 
study reported discordance of ERCC1 expression between 
primary and metastatic tumors.56
 Approximately 25% of lung adenocarcinomas harbor 
KRAS mutations, which predict non-response to EGFR 
TKI therapy. Of the remaining KRAS-negative lung 
adenocarcinomas, B20% harbor EGFR mutations, which 
are associated with responsiveness to EGFR TKI therapy. 
EGFR mutation negative cases may benefit from additional 
testing for the EML4–ALK rearrangement, which will be 
helpful in selecting patients potentially eligible for ALK-
targeted therapy.57
Conclusion 
Biomarkers that can be used to diagnose and monitor therapy 
include CEA, NSE, CYFRA 21-1, AFP, CA 125, CA-19.9, 
and Ferritin. The use of biomarkers in combination can 
improve the accuracy in diagnosing lung cancer. Other 
biomarkers include KRAS mutations, BRAF mutation, 
MET amplification and ERCC1 can be used to see whether 
there are any genetic mutations that lead to lung cancer.
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